医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Longhorn Vaccines & Diagnostics to Present at The 50th Union World Conference on Lung Health

2019年10月23日 PM11:00
このエントリーをはてなブックマークに追加


 

BETHESDA, Md.

Longhorn Vaccines & Diagnostics an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations, will be participating and presenting scientific data at The 50th Union World Conference on Lung Health on October 30 – November 2 in Hyderabad, India. The conference is the largest gathering of clinicians and public health workers, health program managers, policymakers, researchers and advocates working to end the suffering caused by lung disease with a focus specifically on the challenges faced by low-and lower-middle income populations.

Longhorn Vaccines and Diagnostics executive team will lead the following oral abstract session:

Title: Targeted Next-Generation Sequencing Methodology for Characterizing High-Prevalence Multi-Drug Resistance Mycobacterium tuberculosis Mutations
Speaker: Luke T. Daum, Ph.D., Chief Scientific Officer, Longhorn Vaccines & Diagnostics
Date & Time: Friday, November 1 at 10:30 am IST
Location: MR 1.03 & 1.04

About Longhorn Vaccines and Diagnostics

Longhorn Vaccines & Diagnostics is an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations. Longhorn’s core product, PrimeStore® Molecular Transport Medium (MTM), is a patented, FDA approved, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations and drug manufacturers improve the diagnosis and treatment of infectious diseases such as mycobacterium tuberculosis (TB) and Influenza. Unlike standard devices for collecting and transporting TB samples, MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization. Longhorn is based in Bethesda, Maryland.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191023005255/en/

CONTACT

Media:

Sean Leous

Westwicke/ICR PR

Phone: +1.646.677.1839

sean.leous@icrinc.com

同じカテゴリーの記事 

  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report
  • Masimo创始人兼首席执行官Joe Kiani将在智利举行的全球患者安全峰会上谈论人工智能